Načítá se...
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of <7%. Due to growing incidence, late diagnosis and insufficient treatment options, PDAC is predicted to soon become one of the leading causes of cancer-related death. Although...
Uloženo v:
| Vydáno v: | Gut |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5256386/ https://ncbi.nlm.nih.gov/pubmed/27811314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-312539 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|